Some shorts are drawing parallels between Sabizabulin and Lorenlimab following a recently published misleading article by Chris Sandburg in IF. It’s not even an apples to Orange comparison ! This is why..

In March, CytoDyn Leronlimab's Phase III trial, a CCR5 antagonist, failed to hit the primary endpoint of reducing symptoms and missed all secondary endpoints, including if the drug decreased mortality for COVID-19. However, the company placed a positive spin, focusing on a subgroup of 62 patients on mechanical ventilation, arguing that leronlimab caused a 24% decrease in all-cause mortality and a six-day reduction in hospitalization. They then released a second press announcement describing an “age adjustment” analysis alleging leronlimab decreased mortality in older patients.

The FDA stated, “It has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. None of these analyses met statistical significance when using established and reliable analytical methods that correct for multiple comparisons.”$Veru Inc.(VERU)$